Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)

Wednesday, July 2, 2008 General News J E 4
NAPA, Calif., July 1 Senetek PLC(OTC Bulletin Board: SNKTY), a Life Sciences company engaged in thedevelopment of technologies that target the science of healthy aging, todayannounced that effective with the termination of its marketing agreement withTriax Aesthetics LLC for Pyratine-6(TM), all promotion, sales and distributionof Pyratine-6(TM) would be controlled and managed directly by the Company.

Phil Rose, Senetek's Chief Operating Officer stated, "We are building aninfrastructure that has the expertise to establish Pyratine-6(TM) as theleading anti-aging product in the physician channel. The clinical datasupporting Pyratine-6(TM) provides a clear and differential advantage over thecompetition. We are moving forward quickly and strategically without anylooking back. We have the foundation and experience for success."

Bill O'Kelly, Senetek's Chief Financial Officer stated, "We are finalizingthe operating and financial plan associated with the Company's promotion,sales and distribution of Pyratine-6(TM) and we will communicate appropriateaspects of the plan to our shareholders when the process is completed."

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engagedin the development of breakthrough technologies that target the science ofhealthy aging. The Company's extensive research collaborations have resultedin a strong pipeline of patented compounds and products with broad therapeuticapplications and a leading presence in dermatology. Senetek collaborates withestablished specialty pharmaceutical companies in the final development andmarketing of its proprietary products, most recently resulting in thedevelopment of the best-selling anti-aging product sold in the North Americanphysician market. For more information, visit the company's website at

This news release contains statements that may be considered'forward-looking statements' within the meaning of the Private SecuritiesLitigation Reform Act. Forward-looking statements by their nature involvesubstantial uncertainty, and actual results may differ materially from thosethat might be suggested by such statements. Important factors identified bythe Company that it believes could result in such material differences aredescribed in the Company's Annual Report on Form 10-K for the year 2007.However, the Company necessarily can give no assurance that it has identifiedor will identify all of the factors that may result in any particularforward-looking statement materially differing from actual results, and theCompany assumes no obligation to correct or update any forward-lookingstatements which may prove to be inaccurate, whether as a result of newinformation, future events or otherwise.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Children's Healthcare of Atlanta to Open Marcus Au...
ChromaDex, Inc. Announces Completion of Reverse Me...